The intrastratial injection of an adenosine A2 receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease
- 29 June 1999
- journal article
- Published by Elsevier in Brain Research
- Vol. 831 (1-2) , 315-318
- https://doi.org/10.1016/s0006-8993(99)01489-4
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neuronsEuropean Journal of Neuroscience, 1998
- Adenosine A1 Receptor Agonists as Clinically Viable Agents for Treatment of Ischemic Brain DisordersAnnals of the New York Academy of Sciences, 1997
- Adenosine–dopamine receptor–receptor interactions as an integrative mechanism in the basal gangliaTrends in Neurosciences, 1997
- Adenosine Receptors:Selective Agonists and AntagonistsPublished by Springer Nature ,1995
- CGS 15943, An adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the mongolian gerbilLife Sciences, 1994
- EEG power spectra in huntington's disease: Clinical and neuropsychological correlatesNeuropsychologia, 1994
- Excitotoxic injury of the neostriatum: a model for Huntington's diseaseTrends in Neurosciences, 1990
- Glutamate neurotoxicity and diseases of the nervous systemNeuron, 1988
- Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivoBritish Journal of Pharmacology, 1988
- Replication of the neurochemical characteristics of Huntington's disease by quinolinic acidNature, 1986